1.17 USD
0 (0%)
Overall IBIO gets a fundamental rating of 2 out of 10. We evaluated IBIO against 533 industry peers in the Biotechnology industry. Both the profitability and financial health of IBIO have multiple concerns. IBIO is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
IBIO had negative earnings in the past year.
In the past year IBIO has reported a negative cash flow from operations.
In the past 5 years IBIO always reported negative net income.
In the past 5 years IBIO always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of IBIO (-79.26%) is worse than 65.48% of its industry peers.
IBIO's Return On Equity of -123.50% is in line compared to the rest of the industry. IBIO outperforms 40.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -79.26% | ||
| ROE | -123.5% | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IBIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
IBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
IBIO has an Altman-Z score of -20.79. This is a bad value and indicates that IBIO is not financially healthy and even has some risk of bankruptcy.
IBIO has a worse Altman-Z score (-20.79) than 84.62% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that IBIO is not too dependend on debt financing.
IBIO has a Debt to Equity ratio (0.05) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -20.79 |
ROIC/WACCN/A
WACC8.68%
2.3 Liquidity
IBIO has a Current Ratio of 1.59. This is a normal value and indicates that IBIO is financially healthy and should not expect problems in meeting its short term obligations.
IBIO's Current ratio of 1.59 is on the low side compared to the rest of the industry. IBIO is outperformed by 81.05% of its industry peers.
A Quick Ratio of 1.59 indicates that IBIO should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.59, IBIO is doing worse than 80.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.59 |
3. Growth
3.1 Past
IBIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 73.07%, which is quite impressive.
Looking at the last year, IBIO shows a very strong growth in Revenue. The Revenue has grown by 77.78%.
Measured over the past years, IBIO shows a very negative growth in Revenue. The Revenue has been decreasing by -24.59% on average per year.
EPS 1Y (TTM)73.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.09%
Revenue 1Y (TTM)77.78%
Revenue growth 3Y-40.3%
Revenue growth 5Y-24.59%
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 11.54% on average over the next years. This is quite good.
Based on estimates for the next years, IBIO will show a small growth in Revenue. The Revenue will grow by 4.56% on average per year.
EPS Next Y78.88%
EPS Next 2Y36.84%
EPS Next 3Y22.08%
EPS Next 5Y11.54%
Revenue Next Year-37.5%
Revenue Next 2Y-8.71%
Revenue Next 3Y7.72%
Revenue Next 5Y4.56%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
IBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
IBIO's earnings are expected to grow with 22.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.84%
EPS Next 3Y22.08%
5. Dividend
5.1 Amount
IBIO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:IBIO (11/26/2025, 2:21:25 PM)
1.17
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners16.45%
Inst Owner Change11.43%
Ins Owners3.14%
Ins Owner Change0%
Market Cap23.69M
Revenue(TTM)400.00K
Net Income(TTM)-18.38M
Analysts86
Price Target4.2 (258.97%)
Short Float %12.65%
Short Ratio0.66
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-40.87%
Min EPS beat(2)-50.12%
Max EPS beat(2)-31.61%
EPS beat(4)1
Avg EPS beat(4)-19.5%
Min EPS beat(4)-50.12%
Max EPS beat(4)6.05%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.9%
PT rev (3m)-15.34%
EPS NQ rev (1m)33.87%
EPS NQ rev (3m)48.75%
EPS NY rev (1m)32.05%
EPS NY rev (3m)51.52%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 59.23 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.59 | ||
| P/tB | 2.95 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.57
EYN/A
EPS(NY)-0.24
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.76
OCFYN/A
SpS0.02
BVpS0.73
TBVpS0.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -79.26% | ||
| ROE | -123.5% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 2.06% | ||
| Cap/Sales | 4% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.59 | ||
| Altman-Z | -20.79 |
F-Score5
WACC8.68%
ROIC/WACCN/A
Cap/Depr(3y)216.31%
Cap/Depr(5y)243.74%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.09%
EPS Next Y78.88%
EPS Next 2Y36.84%
EPS Next 3Y22.08%
EPS Next 5Y11.54%
Revenue 1Y (TTM)77.78%
Revenue growth 3Y-40.3%
Revenue growth 5Y-24.59%
Sales Q2Q%N/A
Revenue Next Year-37.5%
Revenue Next 2Y-8.71%
Revenue Next 3Y7.72%
Revenue Next 5Y4.56%
EBIT growth 1Y-80.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y18.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.52%
OCF growth 3YN/A
OCF growth 5YN/A
IBIO INC / IBIO FAQ
What is the ChartMill fundamental rating of IBIO INC (IBIO) stock?
ChartMill assigns a fundamental rating of 2 / 10 to IBIO.
What is the valuation status of IBIO INC (IBIO) stock?
ChartMill assigns a valuation rating of 1 / 10 to IBIO INC (IBIO). This can be considered as Overvalued.
Can you provide the profitability details for IBIO INC?
IBIO INC (IBIO) has a profitability rating of 0 / 10.
Can you provide the financial health for IBIO stock?
The financial health rating of IBIO INC (IBIO) is 2 / 10.
Can you provide the expected EPS growth for IBIO stock?
The Earnings per Share (EPS) of IBIO INC (IBIO) is expected to grow by 78.88% in the next year.